Bio: Ethan Perlstein, Ph.D.

Over the course of the last decade first as a graduate student at Harvard and then as a postdoc at Princeton, Dr. Ethan Perlstein developed an approach to studying complex drugs with simple model organisms called evolutionary pharmacology. Last year Dr. Perlstein left academia in the face of “postdocalypse,” declared scientific independence, and decided to apply evolutionary pharmacology to orphan/rare diseases. His journey of professional reinvention includes forays into tweeting, blogging, crowdfunding, and consulting. It culminates in Perlstein Lab, a SF-based biotech startup and public benefit corporation that is focused on precision orphan drug discovery.